Second, we separately analyzed the impact of CD93 on the OS rate for patients with low-grade gliomas (LGG) (Fig. 2c, d) as well as patients with HGG to avoid the effects of heterogeneous differences in various tumoral grades, and we determined that the impact of CD93 on OS was more apparent for HGG patients (Fig. 2e, f). This evidence concerns the gene CD93 and central nervous system cancer.